Positive effect of HPV status on prognostic value of blood lymphocyte-to-monocyte ratio in advanced cervical carcinoma

Table 5 Multivariate analysis of Cox proportional hazards model of 5-year OS and PFS for the patients of the CCRT group (n = 147)

Prognostic factors	OS			PFS
Prognostic factors	Hazard ratio	95 % CI	p value	Hazard ratio	95 % CI	p value
LMR: high versus low	0.251	0.161–0.412	0.013	0.218	0.014–0.582	0.021
HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA	0.132	0.023–0.314	0.001	0.206	0.064–0.516	0.017
Age: ≤46 versus >46	0.323	0.101–0.616	0.072	1.113	0.756–3.561	0.403
FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA	0.174	0.074–0.338	0.024	0.127	0.017–0.528	0.023
pathological type: SCC versus ADC versus ASC versus UDC	0.305	0.056–0.428	0.001	0.275	0.126–0.490	0.031
Lymph node status classification: positive lymph node versus negative lymph node	1.364	0.789–3.238	0.063	2.531	1.476–4.821	0.059
ALC: high versus low	0.458	0.198–0.824	0.021	0.512	0.165–0.928	0.013
AMC: high versus low	0.703	0.149–1.614	0.219	0.982	0.301–2.124	0.533

OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma; UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count

ISSN: 1475-2867